A case of atherotrombotic variant of ischemic stroke in crohn’s disease patient

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Brain stroke is one of the main causes of morbidity and mortality worldwide. It causes great damage not only to the health of the patient, but also to the economy as a whole. Recently, there has been an increase in the frequency of strokes in young and middle-aged patients with chronic immunoinflammatory diseases. The article presents a description of ischemic stroke clinical case caused by cerebral artery atherothrombosis in a male patient with Crohn’s disease who does not have traditional cardiovascular risk factors.

Full Text

Restricted Access

About the authors

Larisa V. Tarasova

I.N. Ulyanov Chuvash State University; Republican Clinical Hospital of the Ministry of Healthcare of the Chuvash Republic; Institute for Advanced Medical Education of the Ministry of Healthcare of the Chuvash Republic

Author for correspondence.
Email: tlarisagast18@mail.ru
ORCID iD: 0000-0003-1496-0689

MD, associate professor, head of the Department of hospital therapy, professor of the Department of public health and healthcare, head of the Department of gastroenterology

Russian Federation, 428015, Cheboksary, 45 Moskovsky Avenue; Cheboksary; Cheboksary

Nadezhda Yu. Kucherova

I.N. Ulyanov Chuvash State University; Republican Cardiological Dispensary of the Ministry of Healthcare of the Chuvash Republic

Email: nadezda_kan@mail.ru
ORCID iD: 0000-0002-9500-3719

postgraduate student of the Department of hospital therapy, cardiologist at the advisory polyclinic

Russian Federation, 428015, Cheboksary, 45 Moskovsky Avenue; 428000, Cheboksary, 29a Fedora Gladkova Str.

References

  1. World Health Organization. Cardiovascular diseases. URL: https://www.who.int/ru/health-topics/cardiovascular-diseases#tab=tab_1 (date of access – 01.08.2023).
  2. Федеральная служба государственной статистики. Доступ: https://rosstat.gov.ru/sdg/data/goal3 (дата обращения – 01.08.2023). [Federal State Statistics Service (Russia). URL: https://rosstat.gov.ru/sdg/data/goal3 (date of access – 01.08.2023) (In Russ.)].
  3. Weissman S., Sinh P., Mehta T.I. et. al. Atherosclerotic cardiovascular disease in inflammatory bowel disease: The role of chronic inflammation. World J Gastrointest Pathophysiol. 2020; 11(5): 104–13. https://dx.doi.org/10.4291/wjgp.v11.i5.104.
  4. Pepe M., Carulli E., Forleo C. et. al. Inflammatory bowel disease and acute coronary syndromes: From pathogenesis to the fine line between bleeding and ischemic risk. Inflamm Bowel Dis. 2021; 27(5): 725–31. https://dx.doi.org/10.1093/ibd/izaa160.
  5. Le Gall G., Kirchgesner J., Bejaoui M. et. al. Clinical activity is an independent risk factor of ischemic heart and cerebrovascular arterial disease in patients with inflammatory bowel disease. 2018; 13(8): e0201991. https://dx.doi.org/10.1371/journal.pone.0201991.
  6. Pemmasani G., Elgendy I., Mamas M.A. et al. Epidemiology and clinical outcomes of patients with inflammatory bowel disease presenting with acute coronary syndrome. Inflamm Bowel Dis. 2021; 27(7): 1017–25. https://dx.doi.org/10.1093/ibd/izaa237.
  7. Nguyen N.H., Ohno-Machado L., Sandborn W.J., Singh S. Infections and cardiovascular complications are common causes for hospitalization in older patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2018; 24(4): 916–23. https://dx.doi.org/10.1093/ibd/izx089.
  8. Pepe M., Cecere A., D’Alessandro P. et. al. Massive stent thrombosis during active ulcerative colitis: The tricky balance between manifest hemorrhagic and concealed thrombotic risk. Clin Exp Med. 2018; 18(4): 481–85. https://dx.doi.org/10.1007/s10238-018-0522-5.
  9. Yarur A.J., Deshpande A.R., Pechman D.M. et. al. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol. 2011; 106(4): 741–47. https://dx.doi.org/10.1038/ajg.2011.63.
  10. Gravina A.G., Dallio M., Masarone M. et. al. Vascular endothelial dysfunction in inflammatory bowel diseases: Pharmacological and nonpharmacological targets. Oxid Med Cell Longev. 2018; 2018: 1–12. https://dx.doi.org/10.1155/2018/2568569.
  11. Vanuzzo D. The epidemiological concept of residual risk. Intern Emerg Med. 2011; 6 Suppl 1: 45–51. https://dx.doi.org/10.1007/s11739-011-0669-5.
  12. Ridker P.M. Will all atherosclerosis patients soon be treated with combination lipid-lowering and inflammation-inhibiting agents? Circulation. 2020; 141(10): 787–89. https://dx.doi.org/10.1161/CIRCULATIONAHA.119.045256.
  13. Ridker P.M. Residual inflammatory risk: Addressing the obverse side of the atherosclerosis prevention coin. Eur Heart J. 2016; 37(22): 1720–22. https://dx.doi.org/10.1093/eurheartj/ehw024.
  14. Магрук М.А., Мосикян А.А., Бабенко А.Ю. Биомаркеры, ассоциированные с атерогенезом: актуальный статус и перспективные направления. Российский кардиологический журнал. 2019; 24(12): 148–152 [Magruk M.A., Mosikyan A.A., Babenko A.Yu. Biomarkers associated with atherogenesis: Current status and promising areas. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2019; 24(12): 148–152 (In Russ.)]. https://dx.doi.org/10.15829/1560-4071-2019-12-148-152. EDN: PBYHYJ.
  15. Ridker P.M., Rifai N., Rose L. et. al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347(20): 1557–65. https://dx.doi.org/10.1056/NEJMoa021993.
  16. Agouridis A.P., Elisaf M., Milionis H.J. An overview of lipid abnormalities in patients with inflammatory bowel disease. Ann Gastroenterol. 2011; 24(3): 181–87.
  17. Zanoli L., Inserra G., Castellino P. Increased cardiovascular risk in subjects with a low prevalence of classic cardiovascular risk factors: The inflammatory bowel disease paradox. Trends Cardiovasc Med. 2015; 25(8): 705–6. https://dx.doi.org/10.1016/j.tcm.2015.04.001.
  18. Filimon A.M., Negreanu L., Doca M. et. al. Cardiovascular involvement in inflammatory bowel disease: Dangerous liaisons. World J Gastroenterol. 2015; 21(33): 9688–92. https://dx.doi.org/10.3748/wjg.v21.i33.9688.
  19. Fumery M., Xiaocang C., Dauchet L. et. al. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. J Crohns Colitis. 2014; 8(6): 469–79. https://dx.doi.org/10.1016/j.crohns.2013.09.021.
  20. Миронова О.Ю., Исайкина М.А., Хасиева С.А. Атеросклероз и сердечно-сосудистый риск у пациентов с воспалительными заболеваниями кишечника. Терапевтический архив. 2021; 93(12): 1533–1538. [Mironova O.I., Isaikina M.A., Khasieva S.A. Аtherosclerosis and cardiovascular risk in patients with inflammatory bowel disease. Terapevticheskiy arkhiv = Therapeutic Archive. 2021; 93(12): 1533–1538 (In Russ.)]. https://dx.doi.org/10.26442/00403660.2021.12.201225. EDN: HJJJXN.
  21. Лищинская А.А., Князев О.В., Каграманова А.В. с соавт. Частота и факторы риска тромбоэмболических осложнений у пациентов с воспалительными заболеваниями кишечника. Терапевтический архив. 2022; 94(2): 172–179. [Lishchinskaya A.A., Knyazev O.V., Kagramanova A.V. et. al. Frequency and risk factors for thromboembolic complications in patients with inflammatory bowel diseases. Terapevticheskiy arkhiv = Therapeutic Archive. 2022; 94(2): 172–179 (In Russ.)]. https://dx.doi.org/10.26442/00403660.2022.02.201367. EDN: CSRIWV.
  22. Andersen N.N., Jess T. Risk of cardiovascular disease in inflammatory bowel disease. World J Gastrointest Pathophysiol. 2014; 5(3): 359–65. https://dx.doi.org/10.4291/wjgp.v5.i3.359.
  23. Wu P., Jia F., Zhang B. et. al. Risk of cardiovascular disease in inflammatory bowel disease. Exp Ther Med. 2017; 13(2): 395–400. https://dx.doi.org/10.3892/etm.2016.3966.
  24. Бабаева Г.Г., Бабаев З.М. Частота выявления некоторых маркеров эндотелиальной дисфункции у больных с воспалительными заболеваниями кишечника. Терапевтический архив. 2018; 90(4): 12–16. [Babayeva G.H., Babayeva Z.M. Frequency of detection of some markers of endothelial dysfunction in patients with inflammatory bowel diseases. Terapevticheskiy arkhiv = Therapeutic Archive. 2018; 90(4): 12–16 (In Russ.)]. https://dx.doi.org/10.26442/terarkh201890412-16. EDN: YVQZQA.
  25. Гриневич В. Б., Радченко В. Г. Микробиота кишечника и метаболический синдром. Экспериментальная и клиническая гастроэнтерология. 2020; 183(11): 11–19. [Grinevich V.B., Radchenko V. G. Gut microbiota and metabolic syndrome. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2020; 183(11): 11–19 (In Russ.)]. https://dx.doi.org/10.31146/1682-8658-ecg-183-11-11-19. EDN: GZNZHU.
  26. Kristensen S.L., Ahlehoff O., Lindhardsen J. et. al. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death – a Danish nationwide cohort study. PLoS One. 2013; 8(2): e56944. https://dx.doi.org/10.1371/journal.pone.0056944.
  27. Feng W., Chen G., Cai D. et al. Inflammatory bowel disease and risk of ischemic heart disease: An updated meta-analysis of cohort studies. J Am Heart Assoc. 2017; 6(8): e005892. https://dx.doi.org/10.1161/JAHA.117.005892.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig.1.

Download (76KB)
Indexing metadata
3. Fig.2.

Download (67KB)
Indexing metadata
4. Fig.3.

Download (71KB)
Indexing metadata

Copyright (c) 2023 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies